Sienna announces distribution partner for Singapore

Latest News

Sienna Cancer Diagnostics (ASX:SDX), a medical technology company developing and commercialising innovative cancer-related tests, has announced its further expansion into Asia with the signing of a distribution partner for Singapore.

Sienna has appointed Mediwell as its non-exclusive distribution partner for the country.

The distribution agreement adds to the presence Sienna has in the Asian market following the appointment of an exclusive distributor for mainland China in 2018. This was followed by South Korea earlier this year.

The agreement allows Mediwell the right to sell Sienna’s in-vitro diagnostic hTERT test to pathology labs and hospitals where it will be used as an adjunct to urine cytology, assisting pathologists and urologists in the diagnosis of bladder cancer. 

Mediwell have extensive experience in medical diagnostics and the supply of related equipment and laboratory supplies to a network of pathology laboratories and hospitals.

According to Mediwell managing director Mr YK Cheng, “This is an exciting opportunity to work with Sienna to bring a clinically useful product to the Singapore market, providing value to doctors and ultimately, their patients. We have already received positive responses from local IHC technology laboratories and have started discussions with local hospitals for evaluation of the test, with a plan for those hospitals to serve as the initial entry points for the test in Singapore.”